Current Hypertension Reports

, Volume 15, Issue 5, pp 470–474

Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Abstract

Hypertension and obesity often coexist, exposing patients to cardiovascular and metabolic risks, particularly type 2 diabetes mellitus. Moreover, obesity may render hypertensive patients treatment resistant. We review how drugs recently approved for obesity or type 2 diabetes mellitus treatment affect blood pressure. The weight-reducing drug lorcaserin induces modest reductions in body weight while slightly improving blood pressure. The fixed low-dose topiramate/phentermine combinations elicit larger reductions in body weight and blood pressure. Concomitant improvements in glucose metabolism, adiposity, and blood pressure differentiate the first clinically available SGLT2 inhibitor dapagliflozin from other oral antidiabetic drugs. Yet, the mechanisms through which metabolic drugs affect blood pressure and their interaction with antihypertensive drugs are poorly understood. Blood pressure-lowering effects of metabolic drugs could be exploited in the clinical management of obese hypertensive patients with and without type 2 diabetes mellitus, particularly in patients with difficult to control arterial hypertension.

Keywords

Hypertension Obesity Type 2 diabetes Blood pressure Lorcaserin Phentermine/topiramate combination Sodium-glucose co-transporter-2 (SGLT2) inhibition 

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bramlage P, Pittrow D, Wittchen HU, Kirch W, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Labeit AM, Klotsche J, Pieper L, et al. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. PLoS One. 2012;7:e52229.PubMedCrossRefGoogle Scholar
  5. 5.
    Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999–2006. Obes Surg. 2011;21:351–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Wofford MR, Anderson Jr DC, Brown CA, et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14:694–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Shibao C, Gamboa A, Diedrich A, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49:27–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Grassi G, Seravalle G, Dell'Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Foster MC, Hwang SJ, Porter SA, et al. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58:784–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.PubMedCrossRefGoogle Scholar
  12. 12.
    Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594–9.PubMedCrossRefGoogle Scholar
  13. 13.
    • Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58. Important report on this clinically challenging entity of hypertension that has only recently received broader attention.PubMedCrossRefGoogle Scholar
  14. 14.
    Molenaar EA, Hwang SJ, Vasan RS, et al. Burden and rates of treatment and control of cardiovascular disease risk factors in obesity: the Framingham Heart Study. Diabetes Care. 2008;31:1367–72.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30:1047–55. Together with reference 16, this paper summarizes all important epidemiological, pathophysiological and treatment information on obesity-associated hypertension.PubMedCrossRefGoogle Scholar
  16. 16.
    •• Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15:14–33. Together with reference 15, this paper summarizes all important epidemiological, pathophysiological, and treatment information on obesity-associated hypertension.CrossRefGoogle Scholar
  17. 17.
    Bakris G, Calhoun D, Egan B. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20:2257–67.PubMedCrossRefGoogle Scholar
  18. 18.
    Ruilope LM, Despres JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens. 2008;26:357–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Jordan J, Scholze J, Matiba B, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord. 2005;29:509–16.Google Scholar
  20. 20.
    Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003;11:1116–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006;79:500–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Heusser K, Engeli S, Tank J, et al. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007;92:1560–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013. doi:10.1111/dom.12085.Google Scholar
  24. 24.
    Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.PubMedCrossRefGoogle Scholar
  25. 25.
    Bharucha AE, Charkoudian N, Andrews CN, et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol. 2008;295:R874–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res. 2011;89:72–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich ). 2006;8:19–28.CrossRefGoogle Scholar
  28. 28.
    Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75–81.PubMedGoogle Scholar
  30. 30.
    Ni W, Fink GD, Watts SW. The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther. 2007;321:485–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577–9.PubMedCrossRefGoogle Scholar
  32. 32.
    •• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56. Important trial on efficacy data of lorcaserin.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77. Important trial on efficacy data of lorcaserin.PubMedCrossRefGoogle Scholar
  34. 34.
    • Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96:837–45. Well-designed study on the weight loss mechanisms of lorcaserin.PubMedCrossRefGoogle Scholar
  35. 35.
    Refusal of the Market authorization for Qsiva (phentermine/topiramate). Available at http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215 pdf 2013.
  36. 36.
    Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother. 2006;7:811–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722–33.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52. Important trial on efficacy data of phentermine/topiramate.PubMedCrossRefGoogle Scholar
  40. 40.
    •• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42. Important trial on efficacy data of phentermine/topiramate.CrossRefGoogle Scholar
  41. 41.
    Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.PubMedCrossRefGoogle Scholar
  42. 42.
    The role of cardiovascular assessment in the pre- and post-approval settings for drugs developed for the treatment of obesity. Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm297240 pdf 2013.
  43. 43.
    Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93:397–404.PubMedCrossRefGoogle Scholar
  44. 44.
    Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14:2873–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:313–27.PubMedGoogle Scholar
  46. 46.
    Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012;32:80–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22.PubMedCrossRefGoogle Scholar
  48. 48.
    • Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31. Well-designed study on the weight loss mechanisms of dapagliflozin.PubMedCrossRefGoogle Scholar
  49. 49.
    Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–33.PubMedCrossRefGoogle Scholar
  50. 50.
    Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;69:852–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Institute of Clinical PharmacologyHannover Medical SchoolHannoverGermany

Personalised recommendations